Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: results of an Italian compassionate use program
Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV coinfected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV)..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:64 |
|---|---|
| Enthalten in: |
Clinical infectious diseases - 64(2017), 5, Seite 680 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Milazzoi, Laura [VerfasserIn] |
|---|
| Links: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC199290412X |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC199290412X | ||
| 003 | DE-627 | ||
| 005 | 20230715043823.0 | ||
| 007 | tu | ||
| 008 | 170512s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20170721 |
| 035 | |a (DE-627)OLC199290412X | ||
| 035 | |a (DE-599)GBVOLC199290412X | ||
| 035 | |a (PRQ)g1762-eaea4b58ad5e5ae6a30622f2a83126e3ed19bd2c713ff29db1fc7c8a5ebd17590 | ||
| 035 | |a (KEY)0124598820170000064000500680ombitasvirparitaprevirritonaviranddasabuvircombina | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 100 | 1 | |a Milazzoi, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: results of an Italian compassionate use program |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV coinfected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV). | ||
| 650 | 4 | |a Complications and side effects | |
| 650 | 4 | |a Liver diseases | |
| 650 | 4 | |a Antiviral agents | |
| 650 | 4 | |a Risk factors | |
| 650 | 4 | |a Dosage and administration | |
| 650 | 4 | |a HIV infection | |
| 650 | 4 | |a Hepatitis C | |
| 650 | 4 | |a Hepatitis | |
| 650 | 4 | |a Risk assessment | |
| 650 | 4 | |a Human immunodeficiency virus--HIV | |
| 650 | 4 | |a Antiretroviral drugs | |
| 700 | 1 | |a Antinori, Andrea |4 oth | |
| 700 | 1 | |a Teti, Elisabetta |4 oth | |
| 700 | 1 | |a Andreoni, Massimo |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases |d Cary, NC : Oxford Univ. Press, 1992 |g 64(2017), 5, Seite 680 |w (DE-627)131041878 |w (DE-600)1099781-7 |w (DE-576)028046099 |x 1058-4838 |7 nnns |
| 773 | 1 | 8 | |g volume:64 |g year:2017 |g number:5 |g pages:680 |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1872127723 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_168 | ||
| 912 | |a GBV_ILN_183 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 64 |j 2017 |e 5 |h 680 | ||